Vumerity medication for relapsing-remitting MS now approved under PBS

01 August 2022

On 1 August 2022, the Government announced that Vumerity® (diroximel fumarate) will be listed under the Pharmaceutical Benefit Scheme (PBS).

This follows the March 2022 approval of Vumerity® for the treatment of relapsing forms of multiple sclerosis (MS) in Australia, by the Therapeutic Goods Association (TGA).

Find out more